- Home
- AZTA vs SUPN Comparison
AZTA vs SUPN Comparison
Compare AZTA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZTA
- SUPN
- Stock Information
- Founded
- AZTA 1978
- SUPN 2005
- Country
- AZTA United States
- SUPN United States
- Employees
- AZTA N/A
- SUPN N/A
- Industry
- AZTA Industrial Machinery/Components
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- AZTA Technology
- SUPN Health Care
- Exchange
- AZTA Nasdaq
- SUPN Nasdaq
- Market Cap
- AZTA 1.8B
- SUPN 1.8B
- IPO Year
- AZTA 1995
- SUPN 2012
- Fundamental
- Price
- AZTA $26.72
- SUPN $31.70
- Analyst Decision
- AZTA Buy
- SUPN Hold
- Analyst Count
- AZTA 3
- SUPN 2
- Target Price
- AZTA $50.67
- SUPN $36.00
- AVG Volume (30 Days)
- AZTA 1.1M
- SUPN 467.8K
- Earning Date
- AZTA 05-07-2025
- SUPN 05-06-2025
- Dividend Yield
- AZTA N/A
- SUPN N/A
- EPS Growth
- AZTA N/A
- SUPN N/A
- EPS
- AZTA N/A
- SUPN 1.11
- Revenue
- AZTA $669,171,000.00
- SUPN $667,997,000.00
- Revenue This Year
- AZTA N/A
- SUPN N/A
- Revenue Next Year
- AZTA $4.89
- SUPN $8.74
- P/E Ratio
- AZTA N/A
- SUPN $28.64
- Revenue Growth
- AZTA 8.56
- SUPN 11.82
- 52 Week Low
- AZTA $23.91
- SUPN $25.53
- 52 Week High
- AZTA $63.58
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- AZTA 44.87
- SUPN 45.77
- Support Level
- AZTA $26.96
- SUPN $31.56
- Resistance Level
- AZTA $28.32
- SUPN $32.85
- Average True Range (ATR)
- AZTA 1.10
- SUPN 0.78
- MACD
- AZTA 0.19
- SUPN -0.08
- Stochastic Oscillator
- AZTA 15.71
- SUPN 13.56
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.